The Committee for Medicinal Products for Human Use (CHMP) of the EMA adopted a positive opinion, recommending the granting of a marketing authorisation for Poherdy in combination with trastuzumab and… read more.
Pfizer Inc. announced the FDA has granted full approval to Braftovi (encorafenib) in combination with cetuximab (Erbitux ) and fluorouracil-based chemotherapy for the treatment of adult patients with… read more.
Despite recent advancements in breast cancer treatments, new breast cancer cases in women are predicted to rise by a third globally from 2.3 million in 2023 to more than 3.5 million in 2050. Similarly, yearly deaths… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to Jazz Pharmaceuticals Research UK Limited for zanidatamab (Ziihera) in adults to treat biliary tract cancer whose cancer… read more.
Pfizer Inc. announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating Braftovi (encorafenib) in combination with cetuximab… read more.
In a Phase 3 randomized trial, Mass General Brigham researchers found that stereotactic radiation targeting individual tumors led to lower symptom burden, better cognitive outcomes, and better day… read more.
Vir Biotechnology announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, Pro -xten dual-masked T-cell engager (TCE) being evaluated in… read more.
Researchers report that patients diagnosed with cancer who subsequently develop a mental disorder are at an increased risk of all-cause death. The findings were published on Feb. 23,… read more.
Iovance Biotherapeutics Inc. announced data demonstrating a best-in-class profile for commercial Amtagvi (lifileucel) with unprecedented response rates in a real-world clinical, retrospective study in patients with advanced (unresectable… read more.
Novocure announced that the FDA approved Optune Pax, Tumor Treating Fields (TTFields) device for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and… read more.
Citius Oncology Inc., the oncology-focused subsidiary of Citius Pharmaceuticals Inc. announced that it has entered into an exclusive distribution agreement with Uniphar , a leading international healthcare services… read more.
American women now have the option of screening for cervical cancer at home, using newly approved self-collection tools. While experts hope this will increase uptake in the under-screened population, a… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
